What are BioSig Technologies, Inc.'s total assets?

BioSig Technologies, Inc. (STEX) holds $173.3M in total assets, up 3823.0% year over year.

How much cash does BioSig Technologies, Inc. have?

BioSig Technologies, Inc. holds $6.9M in cash and equivalents.

Can BioSig Technologies, Inc. cover its short-term obligations?

Its current ratio is 13.90 — current assets exceed current liabilities.

Where does BioSig Technologies, Inc.'s balance sheet data come from?

Every line is extracted from BioSig Technologies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

BioSig Technologies, Inc. STEX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$6.86M+84.0%	$20.32M+14,207%	$11.05M+1,696%	$2.82M+34.0%	$3.73M+796%
Accounts receivable, net	——	——	——	——	$353K+384%
Total current assets	$45.9M+1,052%	$71.9M+18,430%	$14.99M+1,668%	$3M+25.8%	$3.99M+439%
Property and equipment, net	$12K-82.4%	$25K-70.6%	$38K-65.8%	$53K-61.3%	$68K-62.6%
Accumulated depreciation	$1.02M+5.8%	$1.01M+6.3%	$998K+7.9%	$983K+9.3%	$968K+13.3%
Goodwill	$69.76M—	——	——	——	——
Intangible assets, net	$42.42M+15,907%	$44.64M+16,494%	$45.41M+16,473%	$47.92M+17,075%	$265K-6.7%
Deferred tax assets	——	——	——	——	——
Other non-current assets	——	$24.47M+55,518%	$44K0.0%	$44K0.0%	$44K0.0%
Equity method investments	——	——	——	——	——
Long-term investments	——	——	——	——	——
Total investment securities	——	——	——	——	——
Allowance for credit losses	——	——	——	——	——
Total noncurrent assets	$127.41M—	——	——	——	——
Total assets	$173.32M+3,823%	$187.54M+22,174%	$130.51M+9,104%	$109.72M+3,431%	$4.42M+178%
Accrued expenses	——	——	——	——	——
Accrued compensation	$1.18M+524%	$512K+175%	$795K+695%	$617K+147%	$189K-71.9%
Dividends payable	$123K+9.8%	$121K+10.0%	$117K+8.3%	$115K+9.5%	$112K+8.7%
Deposits	——	——	——	——	——
Derivative liabilities	——	——	——	——	——
Total current liabilities	$3.3M+96.7%	$42.79M+1,790%	$125.6M+7,284%	$113.2M+3,704%	$1.68M-67.9%
Deferred tax liabilities	——	——	——	——	——
Other non-current liabilities	——	——	——	——	——
Total liabilities	$13.97M+732%	$54.22M+2,295%	$137.34M+7,974%	$113.2M+3,685%	$1.68M-71.0%
Common stock	500M+150%	500M0.0%	500M+150%	200M0.0%	200M0.0%
Additional paid-in capital	$924.8M+255%	$850.45M+235%	$287.91M+13.4%	$273.34M+8.3%	$260.74M+6.8%
Retained earnings	-$764.81M-196%	-$718.12M-181%	-$294.11M-15.7%	-$278.53M-10.4%	-$258.16M-3.9%
Accumulated other comprehensive income (loss)	-$1.1M—	——	——	——	——
Noncontrolling interests	$256K+783%	$32K+88.2%	$33K+94.1%	$33K+94.1%	$29K+123%
Total stockholders' equity	$158.99M+6,003%	$133.19M+8,726%	-$6.96M-1,618%	-$3.62M-60,183%	$2.61M+160%
Total liabilities and stockholders' equity	$173.32M+3,823%	$187.54M+22,174%	$130.51M+9,104%	$109.72M+3,431%	$4.42M+178%
Other Current Assets Acquired in Business Combination	——	——	——	——	——
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)	$6.86M+84.0%	$20.32M+14,207%	$11.05M+1,696%	$2.82M—	$3.73M—
Sales Tax Receivable	——	——	——	——	——
Assets Acquired in Business Combination	——	——	——	——	——
Deferred Tax Assets and Other Non-Current Assets	——	——	$44K—	$44K—	——
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	$5.82M—	——	——	——	——
Finite-Lived Intangible Assets - Expected Amortization Expense (Year Five)	——	——	——	——	——
Finite Lived Intangible Assets - Gross	$47.88M—	——	——	——	——
Goodwill and Intangible Assets, Net	$12.59M—	——	——	——	——
Indefinite-Lived Research and Development Assets	——	——	——	——	——
Net Operating Loss Carryforwards	——	——	——	——	——
Deferred tax assets	——	——	——	——	——
Intangible assets — net	$42.42M+15,907%	$44.64M+16,494%	$45.41M+16,473%	$47.92M+17,075%	$265K-6.7%
Other intangible assets—net	$42.42M—	——	——	——	——
Goodwill and intangible assets, net	$111.93M—	——	——	——	——
Investments	——	——	——	——	——
Investments	——	——	——	——	——
Other Assets	——	——	——	——	——
Other non-current assets	——	——	$44K—	$44K—	——
Property, plant and equipment at cost	$1.04M0.0%	$1.04M0.0%	$1.04M0.0%	$1.04M0.0%	$1.04M0.0%
Software and Technology Licenses, Net	——	——	$44K—	$44K—	——
Tax Credit Carryforward Valuation Allowance	——	——	——	——	——
Convertible Debt - Current	——	——	——	——	$105K0.0%
Accounts payable and other current liabilities (Note 11)	$3.18M+111%	$2.95M+43.9%	$9.77M+575%	$7.57M+191%	$1.51M-68.7%
Derivative Liability, Current	——	——	——	——	——
Derivative Liabilities - Fair Value	$1.2M—	——	——	——	——
Professional Service Fees Payable	$725K+233%	$705K+80.3%	$1.06M+315%	$303K-75.9%	$218K-86.4%
Total Liabilities Assumed in Business Combination	——	——	——	——	——
Debt Instrument Convertible Conversion Price	——	——	——	——	——
Debt Instrument Face Amount	——	——	——	——	——
Debt Instrument - Effective Interest Rate	——	——	——	——	——
Debt - Unamortized Discount (Premium) and Issuance Costs, Net	——	——	——	——	——
Long-Term Debt - Fair Value	——	——	——	——	——
Accrued taxes and other expenses	——	——	——	——	——
Secured Debt	——	——	——	——	——
Unrecognized Tax Benefits	——	——	——	——	——
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	97.7M+9,672%	49.8M+189%	35.5M+113%	30.8M+104%	1M-91.0%
Common Stock Shares Outstanding	$1.71B—	$6.74B—	$14.04B—	——	——
Convertible Preferred Stock Authorized Shares	1M0.0%	1M0.0%	1M0.0%	1M0.0%	1M0.0%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$98K+308%	$50K+194%	$36K+112%	$31K+107%	$24K+118%
Number of Exercisable Options	2.9M+96.6%	2.7M+108%	2.7M+108%	2.7M+2,269%	1.5M+269%
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Share-Based Payment Award Options Outstanding - Number	2.9M+17.5%	2.7M+8.8%	2.7M+8.8%	2.7M+2,205%	2.5M+357%
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——	$0—	$384.44K—
Share Price	$3.00—	$3.03—	$5.76—	——	——
Temporary Equity Attributable to Parent	$105K0.0%	$105K0.0%	$105K0.0%	$105K0.0%	$105K0.0%
Warrants and Rights Outstanding	1.6M—	1.7M—	2.4M—	——	——
Weighted Average Exercise Price of Outstanding Options	$5.00+549%	$5.00+421%	$0.78-18.7%	$0.77-93.9%	$0.77-97.1%
Cumulative Cost Basis	$1.04M0.0%	$1.04M0.0%	$1.04M0.0%	$1.04M0.0%	$1.04M0.0%
Accrued Consulting Current	——	——	——	——	——
Accrued Insurance Premium Financing	——	——	——	——	——
Accrued Interest Current	——	——	——	——	——
Accrued Office Expense And Other Expense	——	——	——	——	——
Professional service fees	$725K+233%	$705K+80.3%	$1.06M+315%	$303K-75.9%	$218K-86.4%
Accrued Research And Development Expenses	——	——	——	——	——
Prepaid expense and other assets	——	——	——	——	——
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Sales Tax Receivable	——	——	——	——	——
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Developed Technology	——	——	——	——	——
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Legal And Compliance Framework	——	——	——	——	——
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Due From Related Party	——	——	——	——	——
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Trade Name	——	——	——	——	——
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Goodwill	——	——	——	——	——
Cash, cash equivalents and short-term investments	——	——	——	——	——
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable And Accrued Expenses	——	——	——	——	——
Cash and cash equivalents, end of period	$6.86M+84.0%	$20.32M+14,207%	$11.05M+1,696%	$2.82M—	$3.73M—
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1	——	——	——	——	——
Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right	——	——	——	——	——
Class of Warrant or Right, Outstanding	$1.65M—	$1.74M—	$2.41M—	——	——
Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrant Or Rights Exercisable	——	——	——	——	——
Class Of Warrants Or Right Outstanding	——	——	——	——	——
Class Of Warrants Or Rights Exercisable	——	——	——	——	——
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$500M+150%	$500M0.0%	$500M+150%	$200M0.0%	$200M0.0%
Common stock, shares issued (in shares)	$97.72M+303%	$49.81M+189%	$35.46M+113%	$30.79M+104%	$24.25M+117%
Common Stock, Shares, Outstanding	$97.72M+303%	$49.81M+189%	$35.46M+113%	$30.79M+104%	$24.25M+117%
Convertible Debt	——	——	——	——	——
Debt Instrument Annual Principal Payment	——	——	——	——	——
Effective conversion price (per $1,000 of principal amount) per share	——	——	——	——	——
Debt issuances	——	——	——	——	——
Debt Instrument, Fair Value Disclosure	——	——	——	——	——
Debt Instrument Fee Amount	——	——	——	——	——
Less: net unamortized discount	——	——	——	——	——
Deferred Tax Liabilities, Gross	——	——	——	——	——
Deferred income taxes	——	——	——	——	——
Deferred Tax Asset Offset	——	——	——	——	——
Deferred Tax Assets, Gross	——	——	——	——	——
Deferred Tax Assets In Amortization Expense Patents And Trademarks	——	——	——	——	——
Deferred Tax Assets In Charitable Contributions	——	——	——	——	——
Deferred Tax Assets In Interest Expense Limitation	——	——	——	——	——
Deferred Tax Assets In Nonqualified Stock Options	——	——	——	——	——
Deferred Tax Assets In Research Development Tax Credit	——	——	——	——	——
Deferred Tax Assets In Unrealized Gain Loss From Foreign Currency Exchange	——	——	——	——	——
Deferred Tax Assets, Net	——	——	——	——	——
Temporary differences related to Texas Margin Tax	——	——	——	——	——
Deferred Tax Assets, Valuation Allowance	——	——	——	——	——
Deferred Tax Liabilities, Net	——	——	——	——	——
Depreciation Expense	——	——	——	——	——
Derivative Assets Liabilities At Fair Value Net	——	——	——	——	——
Discount Rate	——	——	——	——	——
Unrecognized compensation cost related to non-vested awards	——	——	——	$0—	$384.44K—
Equity Method Investment Outstanding Percentage	——	——	——	——	——
Federal And Provincial Rate	——	——	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$5.01M—	——	——	——	——
2028	$5.82M—	——	——	——	——
2030	$5.82M—	——	——	——	——
Finite Lived Intangible Assets Amortization Expense After Year Four	——	——	——	——	——
2031	——	——	——	——	——
Remainder of 2026	——	——	——	——	——
2027	$5.82M—	——	——	——	——
2029	$5.82M—	——	——	——	——
Finite Lived Intangible Assets Amortization Expense After Year Five	——	——	——	——	——
Finite Lived Intangible Assets Foreign Currency Translation Adjustment	——	——	——	——	——
Gross Carrying Amount	$47.88M—	——	——	——	——
Foreign Acquisition Of Intangible Assets Step Up	——	——	——	——	——
Granted Share Price	——	——	——	——	——
Marketable Securities	——	——	——	——	——
Noncontrolling interests in subsidiaries	$256K+783%	$32K+88.2%	$33K+94.1%	$33K+94.1%	$29K+123%
Other accrued liabilities	——	——	——	——	——
Other Separationrelated Obligations	——	——	——	——	——
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$1M0.0%	$1M0.0%	$1M0.0%	$1M0.0%	$1M0.0%
Prepaid expenses	$15.22M+10,047%	$17.34M+13,883%	$3.9M+3,349%	$152K-6.7%	$150K-31.8%
Prepaid Insurance	——	——	——	——	——
Royalty Rate	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	$2.92M+96.6%	$2.74M+108%	$2.74M+108%	$2.74M+2,269%	$1.49M+269%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$2.92M+17.5%	$2.74M+8.8%	$2.74M+8.8%	$2.74M+2,205%	$2.49M+357%
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number	——	——	——	——	——
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$5+549%	$5+421%	$0.78-18.7%	$0.77-93.9%	$0.77-97.1%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	$1.71B—	$6.74B—	$14.04B—	——	——
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Unvested Total Number Of Shares	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Option Outstanding Weighted Average Exercise Price	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Outstanding Number	——	——	——	——	——
Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable	$2.92M+96.6%	$2.74M+108%	$2.74M+108%	$2.74M+2,269%	$1.49M+269%
Share price (in dollars per share)	$3—	$3.03—	$5.76—	——	——
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares	——	——	——	——	——
Sharebased Compensation Arrangement By Sharebased Payment Award Option Nonvested Number Of Shares	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	$1.71B—	$6.74B—	$14.04B—	——	——
Shares Issued Price Per Share	——	——	——	——	——
Unrecognized tax benefits	——	——	——	——	——
Working Captal Deficit	——	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——	——
Remainder of Fiscal Year 2025	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about BioSig Technologies, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are BioSig Technologies, Inc.'s total assets?: BioSig Technologies, Inc. (STEX) holds $173.3M in total assets, up 3823.0% year over year.
How much cash does BioSig Technologies, Inc. have?: BioSig Technologies, Inc. holds $6.9M in cash and equivalents.
Can BioSig Technologies, Inc. cover its short-term obligations?: Its current ratio is 13.90 — current assets exceed current liabilities.
Where does BioSig Technologies, Inc.'s balance sheet data come from?: Every line is extracted from BioSig Technologies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.